Kinaxo To Analyze Protein PTMs for Boehringer Ingelheim | GenomeWeb
NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies said today that it will use its mass spectrometry platform to quantitatively analyze post-translational modifications of proteins for Boehringer Ingelheim.
 
Kinaxo, a spinout of the Max-Planck Institute of Biochemistry based in Martinsried, Germany, will use its Cellular Target Profiling technology to study the effects of different compounds on proteome-wide signal transduction pathways for the drugmaker.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.